Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Insider Dianne C. Whitfield Sells 2,137 Shares

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Dianne C. Whitfield sold 2,137 shares of the business’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $107,085.07. Following the completion of the transaction, the insider now owns 46,355 shares in the company, valued at $2,322,849.05. This trade represents a 4.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Tarsus Pharmaceuticals Price Performance

Shares of TARS opened at $49.97 on Friday. Tarsus Pharmaceuticals, Inc. has a twelve month low of $20.08 and a twelve month high of $57.28. The stock’s 50 day moving average is $48.48 and its two-hundred day moving average is $45.35. The firm has a market capitalization of $1.92 billion, a PE ratio of -13.12 and a beta of 1.05. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.08. The business had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. Research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Jefferies Financial Group boosted their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Barclays dropped their price target on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Guggenheim restated a “buy” rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. HC Wainwright reaffirmed a “buy” rating and issued a $73.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Finally, Oppenheimer lifted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $63.67.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Crowley Wealth Management Inc. purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $25,000. GF Fund Management CO. LTD. purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $44,000. R Squared Ltd purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $53,000. FMR LLC boosted its stake in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after acquiring an additional 3,537 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $166,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.